Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
P 4 (1)

Trial Status

Terminated1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT04280510Recruiting

Pathogenic Study of Adult Immune Enteropathies

NCT03866538Phase 4Terminated

Budesonide in Patients With Immune Mediated Enteropathies

Showing all 2 trials

Research Network

Activity Timeline